PresseBox
Press release BoxID: 115691 (Hummingbird Diagnostics GmbH)
  • Hummingbird Diagnostics GmbH
  • Im Neuenheimer Feld 519
  • 69120 Heidelberg
  • http://www.hummingbird-diagnostics.com
  • Contact person
  • Eva Sterzel
  • +49 (6221) 6510-300

febit Files Patent Infringement Lawsuit Against Codon Devices

(PresseBox) (Heidelberg, ) Today, febit biotech GmbH announced that it served a patent infringement lawsuit against Codon Devices Inc., Cambridge, MA, in the U.S. District Court for the District of Delaware. febit asserts that Codon Devices is infringing its issued U.S. Patent No. 6,586,211.

febit considers U.S. Patent No. 6,586,211 the cornerstone of its portfolio of more than 15 patents and patent applications worldwide (including Europe, U.S. and Japan) claiming the exclusive use of microarrays for synthetic gene production.

In the lawsuit, febit biotech GmbH seeks an injunction that would prevent Codon Devices from further misappropriating febit's technology and infringing febit's '211 patent. The lawsuit also seeks unspecified monetary damages arising from the Codon Devices' unauthorized use of the patented technology and the continuous wilful infringement of febit's '211 patent.

Hummingbird Diagnostics GmbH

Developing innovative and creative technologies for genomic research is the corporate mission of the febit group, a German-American biotech company. Geniom is a technological and service platform successfully used in basic and applied research of renowned institutions and companies. Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes providing superior time and cost efficiency combined with an unsurpassed spectrum of applications (Geno-, SNP- and Pathogentyping, Enzyme-on-Chip, miRNA-Profiling and many more). With the unique Geniom Technology febit now enters the high-potential market of synthetic biology with a novel method for production of synthetic genes. Using both, highly integrated automation and extensive customizability, febit meets essential needs of current biomedical research.

www.febit.com